Edesa Biotech Inc. (EDSA)

Overview

Edesa Biotech, Inc. is a distinguished clinical-stage biopharmaceutical company deeply immersed in the research and development, manufacture, and commercialization of advanced pharmaceutical solutions aimed at treating inflammatory and immune-related diseases. Established in 2015 and based in Markham, Canada, Edesa Biotech has made significant strides in developing innovative therapies that address the unmet needs in the treatment of severe diseases. With a keen focus on leveraging the latest advancements in biotechnology, Edesa has established itself as a forerunner in the quest to develop groundbreaking treatments that can significantly enhance patient outcomes.

Products and Services

• EB05

  A monoclonal antibody currently in Phase 3 clinical study, EB05 is being developed for the treatment of acute respiratory distress syndrome (ARDS) in Covid-19 patients. This potential therapy embodies Edesa Biotech’s commitment to responding to global health emergencies by targeting the critical pathways involved in severe inflammatory responses.

• EB01

  A non-steroidal anti-inflammatory compound formulated as a topical vanishing cream, EB01 has successfully completed a Phase 2b clinical study for the treatment of chronic allergic contact dermatitis. This innovative treatment reflects the company’s expertise in dermatological conditions, offering a potential new solution for patients suffering from this persistent and discomforting skin ailment.

• EB02

  Extending its anti-inflammatory research into new areas, EB02 is a secretory phospholipase 2 anti-inflammatory cream in development for treating erythema, swelling, and exudation associated with hemorrhoids disease. This product highlights Edesa Biotech’s continuous efforts to explore and address various inflammatory conditions with significant patient impact.

• EB06

  An anti-chemokine ligand 10 (CXCL10) monoclonal antibody, EB06 is being developed to address vitiligo, a condition characterized by the loss of skin color in patches. By targeting specific pathways involved in the inflammatory process of vitiligo, Edesa Biotech aims to provide a novel approach for the treatment of this disorder, showcasing the company's innovative approach to immune-related diseases.

In addition to these product candidates, Edesa Biotech has forged strategic collaboration agreements with NovImmune SA and Yissum Research Development Company to further expand its research and development capabilities. These partnerships focus on developing monoclonal antibodies and other products for a range of therapeutic, prophylactic, and diagnostic applications, both in humans and animals. Specifically, these collaborations are aimed at exploring new uses in topical dermal and anorectal applications, as well as for dermatologic and gastrointestinal conditions, underpinning Edesa Biotech’s broad and diverse approach to addressing health challenges.